Safety of Sinopharm vaccine for people with Multiple Sclerosis: Study of adverse reactions and disease activity

•Generally similar adverse event profile with the general population.•No cases of anaphylaxis or life-threatening reactions after vaccination.•Adverse events more prevalent in those 55 years old and younger.•Adverse events less prevalent in mild EDSS scores.•No increase in relapse rate after vaccination was detected.